Pressure BioSciences (OTCQB: PBIO) (“PBI”)
, a leader in the development and sale of pressure-based instruments, consumables and platform solutions to the worldwide biotechnology and other industries, today announced a remarkable convergence of global research teams declaring pivotal new insights into COVID-19 biology and disease processes. According to the update, all teams selected PBI’s Pressure Cycling Technology (“PCT”) platform for critical sample preparation steps to help ensure that the greatest abundance and diversity of reproducible results would be revealed in the thousands of proteins involved in affected biochemical pathways. “The compelling history of scientists worldwide publishing on PBI’s PCT-based Barocycler system has resulted in its establishment as the method of choice for many teams who recognize that no compromise can be allowed in the critical stage of sample preparation as they work to ensure that the most complete, informative, robust and reproducible data are captured,” said Dr. Alexander V. Lazarev, chief science officer of PBI. “Recent publications and reports from three independent laboratories located on three different continents highlighted the importance of PBI’s highly effective and reproducible PCT sample preparation platform in studies designed to generate a more thorough understanding of the SARS-CoV-2 biology, etiology and human response to infection.”
To view the full press release, visit https://ibn.fm/t4Im4
About Pressure BioSciences Inc.
Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling pressure-based solutions for the worldwide life sciences and other industries. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control biomolecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Pressure BioSciences’ primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) the recently acquired, patented technology from BaroFold Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information about the company, visit www.PressureBioSciences.com
NOTE TO INVESTORS:
The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
InvestorWire is part of the InvestorBrandNetwork.